Thomas G. Wiggans's most recent trade in Jasper Therapeutics Inc was a trade of 7,500 Stock Option (right to buy) done . Disclosure was reported to the exchange on July 3, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Jasper Therapeutics Inc | Wiggans G. Thomas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2025 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Annexon Inc | Thomas G. Wiggans | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 55,000 | 55,000 | - | - | Stock Option (Right to Buy) | |
| Jasper Therapeutics Inc | Thomas G. Wiggans | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Annexon Inc | Thomas G. Wiggans | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 44,000 | 44,000 | - | - | Stock Option (Right to Buy) | |
| Cymabay Therapeutics Inc | Thomas G. Wiggans | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Mar 2024 | 80,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Thomas G. Wiggans | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Mar 2024 | 67,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Thomas G. Wiggans | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Mar 2024 | 25,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Thomas G. Wiggans | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Mar 2024 | 14,010 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Thomas G. Wiggans | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 14,010 | 14,010 | - | - | Stock Option (right to buy) | |
| Annexon Inc | Thomas G. Wiggans | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 24,000 | 24,000 | - | - | Stock Option (Right to Buy) | |
| Cymabay Therapeutics Inc | Thomas G. Wiggans | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2023 | 25,000 | 25,000 | - | - | Stock Option (right to buy) |